CLINICAL PROTOCOL 
Product: VCL-1102 
July 7, 1994 
VICAL INC. 
9373 Towne Centre Dr., Ste. 100 
San Diego, CA 92121 
4.1 Inclusion Criteria 
4.1.1 Histologically confirmed metastasis of malignant disease. 
4.1.2 Patients must have at least one metastatic lesion measurable 
in two dimensions and at least 1 cm in longest diameter. 
4.1.3 Patients must have had either prior standard therapies for 
their disease and have become unresponsive to them, or 
have made the decision that other therapy would not be 
of any major benefit. 
4.1.4 Patients must be adults 18 years of age or older. 
4.1.5 Patients must have adequate bone marrow reserve: WBC 
>3000/mm3, platelets >100,000/mm3 / hemoglobin >9.0 
gm %; adequate renal and liver function: creatinine <_2.0, 
bilirubin < 2.0 mg/DL, SGOT and SGPT <3X the upper 
limit of normal; adequate coagulation: PT and PTT within 
normal limits. 
4.1.6 Patients must have a baseline Kamofsky Performance 
Status (KPS) score of at least 70 (See Appendix II). 
4.1.7 Estimated life expectancy of at least 16 weeks. 
4.1.8 Patients must be able to render signed informed consent. 
4.1.9 Patients must be HIV antibody negative. Hepatitis B 
antigen negative and IL-2 antibody negative. 
4.1.10 Female patients who have child bearing potential must 
use an approved method of contraception and test 
negative for pregnancy. Both male and female patients 
must use contraception during the course of the study. 
4.1.11 Patients must demonstrate immunocompetence by 
having a PHA lymphocyte response in the normal range. 
Recombinant DNA Research, Volume 20 
[607] 
